Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34475526)

  • 21. [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors].
    Yu XW; Rong W; Xu FL; Xu GY; Sun YR; Feng MY
    Ai Zheng; 2007 Nov; 26(11):1204-10. PubMed ID: 17991319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of mucin expression in pancreatobiliary neoplasms.
    Yonezawa S; Higashi M; Yamada N; Yokoyama S; Goto M
    J Hepatobiliary Pancreat Sci; 2010 Mar; 17(2):108-24. PubMed ID: 19787286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.
    Rakha EA; Boyce RW; Abd El-Rehim D; Kurien T; Green AR; Paish EC; Robertson JF; Ellis IO
    Mod Pathol; 2005 Oct; 18(10):1295-304. PubMed ID: 15976813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location.
    Park SY; Lee HS; Choe G; Chung JH; Kim WH
    Virchows Arch; 2006 Jul; 449(1):40-7. PubMed ID: 16645863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis.
    Biemer-Hüttmann AE; Walsh MD; McGuckin MA; Simms LA; Young J; Leggett BA; Jass JR
    Clin Cancer Res; 2000 May; 6(5):1909-16. PubMed ID: 10815915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and molecular characterization of early-onset colorectal cancer.
    Willauer AN; Liu Y; Pereira AAL; Lam M; Morris JS; Raghav KPS; Morris VK; Menter D; Broaddus R; Meric-Bernstam F; Hayes-Jordan A; Huh W; Overman MJ; Kopetz S; Loree JM
    Cancer; 2019 Jun; 125(12):2002-2010. PubMed ID: 30854646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
    Sirinukunwattana K; Domingo E; Richman SD; Redmond KL; Blake A; Verrill C; Leedham SJ; Chatzipli A; Hardy C; Whalley CM; Wu CH; Beggs AD; McDermott U; Dunne PD; Meade A; Walker SM; Murray GI; Samuel L; Seymour M; Tomlinson I; Quirke P; Maughan T; Rittscher J; Koelzer VH;
    Gut; 2021 Mar; 70(3):544-554. PubMed ID: 32690604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
    Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
    [No Abstract]   [Full Text] [Related]  

  • 30. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.
    Loree JM; Pereira AAL; Lam M; Willauer AN; Raghav K; Dasari A; Morris VK; Advani S; Menter DG; Eng C; Shaw K; Broaddus R; Routbort MJ; Liu Y; Morris JS; Luthra R; Meric-Bernstam F; Overman MJ; Maru D; Kopetz S
    Clin Cancer Res; 2018 Mar; 24(5):1062-1072. PubMed ID: 29180604
    [No Abstract]   [Full Text] [Related]  

  • 32. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
    Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
    Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
    González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
    World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential.
    Renaud F; Mariette C; Vincent A; Wacrenier A; Maunoury V; Leclerc J; Coppin L; Crépin M; Van Seuningen I; Leteurtre E; Buisine MP
    Int J Cancer; 2016 Mar; 138(6):1472-81. PubMed ID: 26476272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MUC5B expression in gastric carcinoma: relationship with clinico-pathological parameters and with expression of mucins MUC1, MUC2, MUC5AC and MUC6.
    Pinto-de-Sousa J; Reis CA; David L; Pimenta A; Cardoso-de-Oliveira M
    Virchows Arch; 2004 Mar; 444(3):224-30. PubMed ID: 14758553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands.
    Alos L; Lujan B; Castillo M; Nadal A; Carreras M; Caballero M; de Bolos C; Cardesa A
    Am J Surg Pathol; 2005 Jun; 29(6):806-13. PubMed ID: 15897748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.